Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT [0.03%]
用于allo-HSCT后复发的骨髓恶性肿瘤一线挽救治疗的Venclyxto联合低甲基化药物疗法
Patrizia Chiusolo,Michele Malagola,Fabio Giglio et al.
Patrizia Chiusolo et al.
Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT [0.03%]
allo-HSCT采用pts后环磷酰胺治疗AML原发性GVHD患者的移植结局：ALWP/EBMT研究
Arnon Nagler,Jacques-Emmanuel Galimard,Sarah Kayser et al.
Arnon Nagler et al.
We assessed pGF in 2497 AML patients undergoing HSCT from 8-10/10 HLA-matched UD with PTCy. pGF was defined as failure to achieve an ANC ≥ 0.5 × 109/L by day +30 after HSCT. The day +30 cumulative incidence of ANC was 92.6% (95%CI: 91.5-9...
Impact of Wilms' tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry [0.03%]
Wilms氏肿瘤1基因（WT1）突变对急性髓系白血病异基因造血细胞移植结局影响的多中心队列研究：来自ALWP/EBMT登记的数据
Arnon Nagler,Jordi Esteve,Jacques-Emmanuel Galimard et al.
Arnon Nagler et al.
We compared transplantation outcomes of AML patients with WT1 mutation (mWT1), identified by next-generation sequencing, to those of patients with wild-type WT1 AML (wtWT1). 703 patients were included, 50 with mWT1 and 653 with wtWT1. Patie...
Successful treatment with Tislelizumab and Zanubrutinib in a patient with relapsed/refractory, CD19/CD20 negative Richter's transformed CLL [0.03%]
替雷利珠单抗和赞布替尼治疗复发/难治性、CD19/CD20阴性的里特氏转化慢性淋巴细胞白血病患者取得疗效
Rina Latscha,Dominik Heim,Benjamin Kasenda et al.
Rina Latscha et al.
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT [0.03%]
预处理方案强度评分可预测allo-HCT治疗骨髓纤维化的疗效：EBMT慢性肿瘤工作组的一项研究
Patryk Sobieralski,Tomasz Czerw,Luuk Gras et al.
Patryk Sobieralski et al.
Outcomes in myelofibrosis (MF) patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) appear unaffected by the intensity of the preparative regimen, defined traditionally as myeloablative (MAC) or reduced intensity con...
Multiple myeloma incidence, transplant utilization, and mortality- impact of social vulnerability [0.03%]
社会脆弱性对多发性骨髓瘤的发病率、移植利用和死亡率的影响
James Fan Wu,Noel Estrada-Merly,Yuhong Zhou et al.
James Fan Wu et al.
Upfront memory T cell add-back with haploidentical TCRαβ-depleted graft in adults with haematological malignancies: a nationwide, multicentre, single-arm, prospective study [0.03%]
TCRαβ单倍体相合移植联合移植前记忆T细胞回输治疗血液系统恶性肿瘤的多中心前瞻性研究
Liang-Piu Koh,Yeh Ching Linn,Yang Liang Boo et al.
Liang-Piu Koh et al.
In haploidentical hematopoietic cell transplantation (Haplo-HCT), in vivo or ex vivo T-cell depletion (TCD) can prevent graft-versus-host disease (GVHD) but increase risk of infection and relapse. We hypothesized that TCRαβ-depleted allog...
Preserved measles immunity after allogeneic hematopoietic stem cell transplantation in a cohort of mainly αβ T-cell-depleted graft recipients [0.03%]
单倍体造血干细胞移植后主要供者缺乏αβT细胞的受者的 measles 免疫记忆
M J M Janssen,M A de Witte,L G M Daenen et al.
M J M Janssen et al.
Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia [0.03%]
比较急性髓系白血病首次完全缓解时单份脐带血移植和使用移植后环磷酰胺的半相合移植
Masamitsu Yanada,Satoshi Yamasaki,Shohei Mizuno et al.
Masamitsu Yanada et al.
Choosing an optimal alternative donor is an important clinical concern in allogeneic hematopoietic cell transplantation (HCT). In Japan, single-unit umbilical cord blood transplantation (UCBT) has been widely used in the last two decades, w...
Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease [0.03%]
Belumosudil及其与鲁索利替尼联合治疗难治性慢性移植物抗宿主病的现实世界经验
Gagan Raju,Moneeza Walji,David Nemirovsky et al.
Gagan Raju et al.
Belumosudil is approved after failure of ≥2 lines of therapy in chronic graft-versus-host disease cGVHD. However, real-world data is limited. We conducted a retrospective analysis of 67 patients with steroid-refractory or dependent (SR/SD)...